Business, energy, technology, markets and global industry news from Business News Today

Catalent

PharmaDeviceNews Catalent
Pharma & Biotech

Catalent’s Elpida Therapeutics deal shows why AAV manufacturing is still a strategic choke point

Ultra-rare gene therapies need more than science. Elpida’s Catalent deal tests whether AAV manufacturing can keep patients within reach.

Read More
Representative image illustrating ophthalmic gene therapy research and retinal disease treatment. Israel’s early access approval for GS010/LUMEVOQ highlights shifting regulatory pathways for rare vision‑loss conditions like Leber Hereditary Optic Neuropathy.
Pharma & Biotech

GenSight Biologics gets green light for GS010 in Israel: What this means for LHON patients and regulators

GenSight Biologics S.A. has received approval from Israel’s Ministry of Health to provide early access treatment with its investigational gene therapy GS010/LUMEVOQ (lenadogene nolparvovec) for individual patients diagnosed with ND4-related Leber Hereditary Optic Neuropathy (LHON). This authorization permits bilateral intravitreal injections under compassionate use protocols, with treatments expected to begin in the first quarter of

Read More